


Pharmaceuticals & Biotechnology | Large Cap
Zydus Lifesciences demonstrates a strong financial standing, particularly excelling in solvency, growth, coverage, and profitability. The company efficiently manages its debt and showcases substantial growth in revenue, operating profit, and earnings per share. Strong coverage ratios indicate a robust ability to meet interest and dividend obligations. Excellent profitability metrics, including high returns on capital, equity, and assets, further underscore the company's financial health. However, there are areas needing attention, notably in liquidity and efficiency. While the company maintains a reasonable liquidity position, it is not exceptionally strong. Efficiency ratios reveal challenges in asset utilization, especially concerning fixed assets, inventory, and receivables. Capital expenditure is also relatively high, which could impact short-term cash flow. Despite these challenges, Zydus Lifesciences' strong performance in key areas suggests a positive outlook, driven by growth and profitability.
Zydus Lifesciences demonstrates a strong financial standing, particularly excelling in solvency, growth, coverage, and profitability. The company efficiently manages its debt and showcases substantial growth in revenue, operating profit, and earnings per share. Strong coverage ratios indicate a robust ability to meet interest and dividend obligations. Excellent profitability metrics, including high returns on capital, equity, and assets, further underscore the company's financial health. However, there are areas needing attention, notably in liquidity and efficiency. While the company maintains a reasonable liquidity position, it is not exceptionally strong. Efficiency ratios reveal challenges in asset utilization, especially concerning fixed assets, inventory, and receivables. Capital expenditure is also relatively high, which could impact short-term cash flow. Despite these challenges, Zydus Lifesciences' strong performance in key areas suggests a positive outlook, driven by growth and profitability.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
32.53
Industry Median
32.38
Large Cap Median
31.52
P/E RATIO
22.97
P/B RATIO
4.28
Industry Median
3.38
Large Cap Median
5.32
P/S RATIO
4.26
Industry Median
3.65
Large Cap Median
5.79
Others
PEG RATIO
0.00
EV/EBITDA RATIO
13.94
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1150.8 as on Jul 10, 2026.
The company demonstrates robust growth across key metrics. The revenue growth rate is impressive, indicating strong market demand and effective sales strategies. The operating profit growth rate is also substantial, showing improved operational efficiency and cost management. The earnings per share (EPS) growth is exceptional, reflecting increased profitability and shareholder value. The asset growth rate indicates that the company is expanding its asset base. The net income growth rate is also significant, confirming overall financial health. The weighted average calculation further reinforces this positive trend, highlighting consistent and sustainable growth patterns.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 1.08 | 12.92 | 13.4 | 18.9 | 16.81 |
| Operating Profit Growth Rate | -0.06 | 15.5 | 39.48 | 31.09 | 20.08 |
| Earnings Per Share (EPS) Growth | 110.32 | -55.81 | 98.04 | 17.23 | 11.39 |
| Asset Growth Rate | 16.31 | -7.52 | 12.8 | 27.24 | 42.84 |
| Net Income Growth Rate | 111.35 | -54.7 | 89.91 | 17.62 | 9.65 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Abbott India Ltd | 8.68 | 37.19 | Neutral | 1892.00 | 730.39 | 1552.00 |
| 2 | Glaxosmithkline Pharmaceuticals Ltd | 8.38 | 39.87 | Neutral | 1309.00 | 59.73 | 1036.00 |
| 3 | Alkem Laboratories Ltd | 8.08 | 29.45 | Neutral | 3005.00 | 182.76 | 2351.00 |
| 4 | Lupin Ltd | 7.84 | 21.40 | Neutral | 8816.00 | 139.24 | 5355.00 |
| 5 | Cipla Ltd | 7.62 | 29.98 | Neutral | 5883.00 | 43.51 | 3862.00 |
| 6 | Mankind Pharma Ltd | 7.61 | 54.49 | Highly Overvalued | 3617.00 | 49.34 | 1938.00 |
| 7 | Zydus Lifesciences Ltd | 7.60 | 22.97 | Neutral | 8475.00 | 35.69 | 5124.00 |
| 8 | Laurus Labs Ltd | 7.10 | 93.43 | Neutral | 1778.00 | 13.71 | 890.00 |
| 9 | Dr Reddys Laboratories Ltd | 6.68 | 24.75 | Neutral | 6454.00 | 38.57 | 4158.00 |
| 10 | Glenmark Pharmaceuticals Ltd | 6.36 | 47.30 | Neutral | 4572.00 | -7.12 | 1362.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Concall Report⬤3rd Jul 26
Q4 FY26 Earnings Conference Call
BULLISH SENTIMENT
Annual Report⬤2nd Jul 26
Annual Report 2025-26
UNDEFINED SENTIMENT
Concall Report⬤2nd Jul 26
Q4 FY26 Earnings Conference Call
BULLISH SENTIMENT
Concall Report⬤2nd Jul 26
Q4 FY26 Earnings Conference Call
BULLISH SENTIMENT